Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

eet as at December 31, 2012 and are sourced from Elan's 20-F SEC filing on February 12, 2013 for the financial year ended December 31, 2012. This calculation has been amended from the calculation included in Appendix II of the Proposal Announcement to include the impact of the US$29.9 million funding provided to Janssen AI in January 2013 (after the end of Elan's last reported financial year).

All amounts contained within this document referred to by "US$" and "c" refer to the US dollar and US cents.

Any reference to "subsidiary undertaking", "associated undertaking" and "undertaking" have the meanings given by the European Communities (Companies: Group Accounts) Regulations, 1992.

Any reference to "subsidiary" has the meaning given to it by Section 155 of the Irish Companies Act 1963, as amended.

Any references to any provision of any legislation shall include any amendment, modification, re-enactment or extension thereof. Any reference to any legislation is to Irish legislation unless specified otherwise.

Words importing the singular shall include the plural and vice versa and words supporting the masculine shall include the feminine or neuter gender.


[1] Net cash calculated in Appendix VI (including the Janssen AI funding commitment relating to bapineuzumab).

[2] Per Elan stock numbers in this section are based on 602.0 million fully diluted shares outstanding at the Proposal Price, as calculated in Appendix VI.

[3] 2020 being the time at which the primary U.S. patent relating to Tysabri and covering the relevant humanized antibody expires. Extracted from Elan's 20-F SEC filing on February 12, 2013 for the financial year ended December 31, 2012.

[4] Referenced in CallStreet transcript of the Tysabri Conference Call on February 6, 2013.

[5] On the basis of Elan's announcement of its results for the 2012 financial year made on February 6, 2013.

[6] US$60-80 million expected this year,
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Santa Paula, CA (PRWEB) September 15, 2014 ... of long term implantable silicones for the medical ... strength, responsive silicone gel for the implantable medical ... incorporates a unique crosslink technology delivering a silicone ... adhesion. The Dual Matrix technology consists of ...
(Date:9/15/2014)... September 15, 2014 Hydro Dynamics, ... announced today that it will be partnering with ... ( http://www.proteaf.com ) for implementing its Shock Wave ... continuous processing. Continuous flow chemistry through process ... pharmaceutical and petrochemical markets for decades. The ...
(Date:9/12/2014)... magnet using an electric field (magnetoelectric memory [MEM] ... next-generation technology for information processing and storage. Multiferroic ... due to the coexistence of electric and magnetic ... spontaneous electric and magnetic polarizations is rare in ... the MEM effect. This article briefly reviews a ...
(Date:9/12/2014)... -- On Thursday, September 11, 2014, the NASDAQ ... Average finished the day 0.12% lower at 17,049.00, and the ... broad based as seven out of ten sectors ended the ... ended the day at 741.83, down 0.33%, while the index ... initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Oct. 31, 2011 Reportlinker.com announces that ... in its catalogue: US ... http://www.reportlinker.com/p0397796/US-Intranasal-Drug-Delivery-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology This report ... Delivery in US$ Million by the following ...
... iBio, Inc. (NYSE AMEX: IBIO ) ... Patent and Trademark Office for US Patent 8,058,511, entitled ... extends iBio,s patent coverage of viral vectors comprising its ... developed by scientists at iBio,s research collaborator, the Fraunhofer ...
... BETHESDA, Md., Oct. 28, 2011 , ... innovator in biotechnology for therapy in diabetes, metabolic syndrome ... services to food, supplement, biotechnology and pharmaceutical companies – ... sell $1.25 million of shares of its common stock ...
Cached Biology Technology:US Intranasal Drug Delivery Industry 2US Intranasal Drug Delivery Industry 3US Intranasal Drug Delivery Industry 4US Intranasal Drug Delivery Industry 5US Intranasal Drug Delivery Industry 6US Intranasal Drug Delivery Industry 7US Intranasal Drug Delivery Industry 8US Intranasal Drug Delivery Industry 9US Intranasal Drug Delivery Industry 10iBio Announces New US Patent for iBioLaunchâ„¢ Technology 2iBio Announces New US Patent for iBioLaunchâ„¢ Technology 3Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 2Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 3
(Date:9/15/2014)... carbon-halogen bonds are produced naturally across all kingdoms of ... with a broad range of biological activities. The presence ... profound influence on their molecular properties. , ... been to find the late-stage, site-specific incorporation of a ... an sp C-H bond (one of the most inert ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Research suggests that genes that affect hearing and cognitive ... the ability to understand and perceive rhythm, pitch, timbre, ... authors of a BioEssays article explain that ... within a population, with the majority of individuals having ... a complex trait attributable to several underlying genes, and ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... about Arctic climate variation during an ancient episode of ... climate variability in the greenhouse world of the Late ... probably would not greatly change the climatic influence associated ... the El Nio Southern Oscillation (ENSO) or ...
... Springer journals Frontiers of Medicine and Protein ... important literature database for medical and biomedical articles, in January. ... publishing partner Higher Education Press. Both journals are part of ... 90 Springer journals. Frontiers in Medicine has a ...
... Ancient stone faces carved into the walls of a well-known ... searching for fossils of extinct giant rats., The team of archaeologists ... tip of East Timor. "Looking up from the cave floor ... on what seemed to be a weathered carving," CSIRO,s Dr Ken ...
Cached Biology News:Arctic climate variation under ancient greenhouse conditions 2Arctic climate variation under ancient greenhouse conditions 3Research literature from China listed in Medline 2Giant rats lead scientists to ancient face carvings 2
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: